Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Sep;68(3):133-137.
doi: 10.4103/jpgm.JPGM_78_21.

An audit of safety reporting in randomized controlled trials over a five-year period in a high impact factor journal

M Konwar  1 , A Mamde  1 , P Patankar  2 , U M Thatte  1 , N J Gogtay  1
Affiliations

An audit of safety reporting in randomized controlled trials over a five-year period in a high impact factor journal

M Konwar et al. J Postgrad Med. 2022 Jul-Sep.

Abstract

Background: Randomized controlled trials [RCTs] form the corner-stone of evidence-based medicine. RCTs published in high impact factor journals such as the New England Journal of Medicine [NEJM] are a key driver of clinical practice and policy decisions. RCTs are expected to report both efficacy and safety, however, safety reporting in many studies tends to be poor. The present audit was undertaken with the primary objective of evaluating safety reporting during a five-year period in all RCTs published in the NEJM.

Methods: PubMed alone was searched for RCTs published in NEJM from 2013-17. Each RCT was searched for the following outcome measures -whether the trial was sponsored by pharmaceutical industry or investigator initiated, phase of trial, nature of intervention and therapeutic area in terms of reporting of safety outcomes [with 'P values' or '95% confidence interval'].

Results: A total of n=623 articles reported safety outcomes of which 275/623 (44.1%) articles reported statistics for safety outcome. There was significant difference in reporting of safety statistics between investigator initiated studies and pharmaceutical industry sponsored studies, [cOR=4.0, 95% CI 2.8- 5.5 P < 0.001]; phase 3 and phase 4 trials, [cOR 0.67, 95% CI 0.5 - 0.9, P = 0.02]; trials involving drugs and surgery, [ cOR 2.07, 95% CI 1.2-3.5, P = 0.01] and in therapeutic areas, cardiovascular and oncology [cOR 0.26, 95% CI 0.1-0.4, P < 0.0001].

Conclusions: Safety reporting in RCTs continues to take a back seat relative to efficacy reporting and is worse for pharmaceutical industry funded studies. Safety reporting should be emphasized in the CONSORT guidelines.

Keywords: Investigator-initiated trial; P-value; randomized controlled trial; safety outcome.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Flow chart showing selection process of the studies
See this image and copyright information in PMC

Comment in

References

    1. Sim I, Olasov B, Carini S. An ontology of randomized controlled trials for evidence-based practice: Content specification and evaluation using the competency decomposition method. J Biomed Inform. 2004;37:108–19. - PubMed
    1. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169:1756–61. - PubMed
    1. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher G, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337–48. - PubMed
    1. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74. - PMC - PubMed
    1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA. 2001;285:437–43. - PubMed